세계의 올리고뉴클레오티드 합성 시장 예측(-2030년) : 제품별, 용도별, 최종사용자별, 지역별

Oligonucleotide Synthesis Market by Product (Drugs (ASO, siRNA)), Synthesized Oligos (Product (Primers, Probes)), Type (Custom, Predesigned), Reagents, Equipment, Application (Therapeutic (Rare Diseases), Research, Diagnostics) - Global Forecast to 2030

US $ 4,950 ￦ 7,146,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,650 ￦ 9,601,000

PDF (5-user License)

PDF 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,150 ￦ 11,766,000

PDF (Corporate License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 이용 인원에 제한은 없으나, 국내에 있는 사업장만 해당되며, 해외 지점 등은 포함되지 않습니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,000 ￦ 14,438,000

PDF (Global License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. (100% 자회사는 동일 기업으로 간주됩니다.) 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

올리고뉴클레오티드 합성 시장 규모는 예측 기간 중 18.6%의 CAGR로 확대하며, 2025년 105억 달러에서 2030년에는 247억 달러에 달할 것으로 예측됩니다.

이 시장의 성장은 프라이머 및 프로브와 같은 합성 올리고뉴클레오티드에 대한 여러 연구 및 진단 용도 수요 증가와 같은 여러 요인에 의해 주도되고 있습니다. 올리고뉴클레오티드 합성에 대한 기술 발전 증가도 예측 기간 중 시장 성장에 기여할 것으로 예측됩니다.

조사 범위
조사 대상연도	2024-2030년
기준연도	2024년
예측 기간	2024-2030년
검토 단위	금액(10억 달러)
부문	제품별, 용도별, 최종사용자별, 지역별
대상 지역	북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카

제품별로는 올리고뉴클레오티드 기반 의약품, 합성 올리고뉴클레오티드, 시약 및 소모품, 기기로 구분되며, 2024년에는 올리고뉴클레오티드 기반 의약품 부문이 가장 큰 시장 점유율을 차지할 것으로 예측됩니다. 이 부문의 큰 점유율은 특히 희귀 및 유전성 질환에서 이러한 치료법이 점점 더 많이 받아들여지고 있으며, 그 성공이 입증되고 있기 때문입니다. 안티센스 올리고뉴클레오티드(ASO)와 작은 간섭 RNA(siRNA)와 같은 의약품은 질병을 유발하는 유전자를 표적으로 하여 정확하고 맞춤화된 치료를 제공합니다. 이러한 수요 증가는 RNA 표적 치료제 및 전달 시스템의 발전, 유전성 질환의 유병률 증가, RNA 기반 치료법 연구개발에 대한 막대한 투자에 의해 촉진되고 있습니다.

올리고뉴클레오티드 합성 시장은 치료용, 연구용, 진단용으로 구분되며, 2024년에는 치료용 분야가 가장 큰 시장 점유율을 차지할 것으로 예측됩니다. 이 시장의 성장은 신경질환 및 희귀질환 치료에 안티센스 및 siRNA와 같은 올리고를 사용함으로써 촉진되고 있으며, CVD 및 암 치료로의 적용 확대를 위한 연구가 진행되고 있습니다. 합성 기술의 발전으로 효율적이고 비용 효율적인 치료 접근법에 대한 수요가 증가하고, 분자 질환 메커니즘에 대한 종합적인 이해는 혁신적인 치료 표적의 발견을 보장하여 이 분야 시장 성장에 기여할 것으로 예측됩니다.

2024년 북미가 가장 큰 시장 점유율을 차지했습니다. 이러한 우위는 주요 업계 진입자들의 강력한 입지와 올리고뉴클레오티드 기반 치료법의 발전에 전념하는 연구 구상의 급격한 증가에 힘입은 것입니다. 또한 북미의 탄탄한 의료 인프라와 유리한 상환 정책은 이러한 혁신적인 치료법의 광범위한 채택을 촉진하고, 그 결과 이 지역에서의 연구 적용을 촉진하고 있습니다. 수많은 세계 기업이 집적되어 있는 것도 이 시장의 리더십에 크게 기여하고 있습니다.

세계의 올리고뉴클레오티드 합성 시장에 대해 조사했으며, 제품별, 용도별, 최종사용자별, 지역별 동향 및 시장에 참여하는 기업의 개요 등을 정리하여 전해드립니다.

목차

제1장 서론

제2장 조사 방법

제3장 개요

제4장 주요 인사이트

제5장 시장 개요

• 서론
• 시장 역학
• 업계 동향
• 고객 비즈니스에 영향을 미치는 동향/혼란
• 밸류체인 분석
• 에코시스템 분석
• 기술 분석
• 가격 분석
• 특허 분석
• 파이프라인 분석
• 무역 분석
• 2025-2026년의 주요 컨퍼런스와 이벤트
• 관세와 규제 상황
• Porter's Five Forces 분석
• 주요 이해관계자와 구입 기준
• 사례 연구 분석
• 투자/자금조달 시나리오
• 올리고뉴클레오티드 합성 시장에서 생성형 AI의 영향
• 트럼프 관세의 영향 개요 : 올리고뉴클레오티드 합성 시장

제6장 올리고뉴클레오티드 합성 시장(제품별)

• 서론
• 올리고뉴클레오티드계 약제
• 합성 올리고뉴클레오티드
• 시약과 소모품
• 장비

제7장 올리고뉴클레오티드 합성 시장(용도별)

• 서론
• 치료
• 연구
• 진단

제8장 올리고뉴클레오티드 합성 시장(최종사용자별)

• 서론
• 병원
• 제약·바이오테크놀러지 기업
• 진단 검사실
• CRO와 CMO
• 학술 조사기관

제9장 올리고뉴클레오티드 합성 시장(지역별)

• 서론
• 북미
  • 북미 : 거시경제 전망
  • 미국
  • 캐나다
• 유럽
  • 유럽 : 거시경제 전망
  • 독일
  • 영국
  • 프랑스
  • 이탈리아
  • 스페인
  • 기타
• 아시아태평양
  • 아시아태평양 : 거시경제 전망
  • 중국
  • 일본
  • 인도
  • 호주
  • 한국
  • 기타
• 라틴아메리카
  • 라틴아메리카 : 거시경제 전망
  • 브라질
  • 멕시코
  • 아르헨티나
  • 기타
• 중동
  • 중동 : 거시경제 전망
  • GCC 국가
  • 기타
• 아프리카
  • 시장의 성장을 지원하는 헬스케어 인프라의 개선
  • 아프리카 : 거시경제 전망

제10장 경쟁 구도

• 서론
• 주요 참여 기업의 전략/강점
• 매출 분석(연구 및 진단)
• 시장 점유율 분석
• 기업 평가 매트릭스 : 주요 참여 기업(연구 및 진단), 2024년
• 기업 평가 매트릭스 : 주요 참여 기업(치료), 2024년
• 기업 평가 매트릭스 : 스타트업/중소기업, 2024년
• 기업 평가와 재무 지표
• 브랜드/제품 비교 분석
• 경쟁 시나리오

제11장 기업 개요

• 주요 참여 기업(연구 및 진단)
  • DANAHER CORPORATION
  • THERMO FISHER SCIENTIFIC INC.
  • MERCK KGAA
  • LGC LIMITED
  • EUROFINS SCIENTIFIC
  • AGILENT TECHNOLOGIES, INC.
  • KANEKA CORPORATION
  • MARAVAI LIFESCIENCES
  • AZENTA US INC.
  • TWIST BIOSCIENCE
  • GENSCRIPT
• 주요 참여 기업(치료)
  • BIOGEN
  • ALNYLAM PHARMACEUTICALS, INC.
  • SAREPTA THERAPEUTICS, INC.
  • ASTRAZENECA
  • ASTELLAS PHARMA INC.
  • JAZZ PHARMACEUTICALS PLC
  • NIPPON SHINYAKU, CO. LTD.
  • IONIS PHARMACEUTICALS, INC.
  • NOVARTIS AG
• 기타 기업
  • OLIGOMAKER APS(PART OF TAG COPENHAGEN A/S)
  • BIOLEGIO B.V.
  • BIOLYTIC LAB PERFORMANCE, INC.
  • BIOCOMMA LIMITED
  • REVVITY(SUBSIDIARY OF HORIZON DISCOVERY LTD.)
  • BIO-SYNTHESIS, INC.
  • CREATIVE BIOGENE
  • REPROCELL INC.(THROUGH SUBSIDIARY BIOSERVE)

제12장 부록

KSA

영문 목차

영문목차

The oligonucleotide synthesis market is projected to reach USD 24.7 billion by 2030 from USD 10.5 billion in 2025, at a CAGR of 18.6% during the forecast period. The growth of this market is driven by several factors, such as the increasing demand for synthesized oligonucleotides like primers & probes for several research & diagnostic applications. Rising technological advancements in oligonucleotide synthesis are also expected to contribute to market growth during the forecast period.

Scope of the Report
Years Considered for the Study	2024-2030
Base Year	2024
Forecast Period	2024-2030
Units Considered	Value (USD billion)
Segments	Product, Application, End User, and Region
Regions covered	North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa

By product, the oligonucleotide-based drugs segment accounted for the largest share of the market in 2024.

By products, the market is segmented into oligonucleotide-based drugs, synthesized oligonucleotides, reagents & consumables, and equipment. In 2024, the oligonucleotide-based drugs segment accounted for the largest share of the market. The large share of this segment can be attributed to the growing acceptance of these treatments and their proven success, especially for rare & hereditary diseases. Medications such as antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) target disease-causing genes, providing precise and personalized treatments. This growing demand is fueled by advancements in RNA-targeted therapies and delivery systems, the rising prevalence of genetic diseases, and significant investments in research and development of RNA-based treatments.

In 2024, by application, the therapeutic applications segment accounted for the largest share of the market.

The oligonucleotide synthesis market is segmented into therapeutic applications, research applications, and diagnostic applications. In 2024, the therapeutic applications segment accounted for the largest share of the market. The growth of this market is fueled by the use of oligos such as antisense and siRNA for the treatment of neurological & rare diseases, with ongoing research aiming to expand applications into the treatment of CVD and cancer. Advancements in synthesis technology are expected to fuel the demand for efficient & cost-effective therapeutic approaches, with a comprehensive understanding of molecular disease mechanisms ensuring the discovery of innovative therapeutic targets, thereby contributing to market growth in this segment.

In 2024, North America accounted for the largest share of the oligonucleotide synthesis market.

In 2024, North America accounted for the largest market share, a dominance fueled by the strong presence of key industry players and a significant surge in research initiatives dedicated to advancing oligonucleotide-based therapeutics. Additionally, North America's well-established healthcare infrastructure and favorable reimbursement policies facilitate the widespread adoption of these innovative treatments, consequently driving research applications in the region. The concentration of numerous global entities also significantly contributes to this market leadership.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Tier 1-25%, Tier 2-35%, and Tier 3- 40%
• By Designation: C-level Executives - 30%, Directors- 45%, and Others- 25%
• By Region: North America -35%, Europe - 25%, the Asia Pacific -15%, Latin America -10%, the Middle East- 10%, and Africa- 5%

Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Eurofins Scientific (Luxembourg), LGC Limited (UK), Agilent Technologies, Inc. (US), Kaneka Corporation (Japan), Maravai LifeSciences (US), Azenta US Inc. (US), Twist Bioscience (US), and GenScript (US) are some of the key companies profiled in the report offering products for research & diagnostic applications.

Biogen (US). Alnylam Pharmaceuticals, Inc. (US), Sarepta Therapeutics, Inc. (US), AstraZeneca (UK), Astellas Pharma Inc. (Japan), Jazz Pharmaceuticals Plc (Ireland), Nippon Shinyaku, Co. Ltd. (Japan), Ionis Pharmaceuticals, Inc. (US), and Novartis AG (Switzerland) are some of the key companies profiled in the report offering products for therapeutic applications.

Research Coverage:

This research report categorizes oligonucleotide synthesis market by Product (Oligonucleotide-based drugs, synthesized oligonucleotide, reagents & consumables, and equipment), application (therapeutic applications, research applications, and diagnostic applications), end user (hospitals, pharmaceutical & biotechnology companies, diagnostic laboratories, CROs & CMOs, and academic & research institutes), and region (North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa).

The report's scope covers detailed information regarding the primary factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the oligonucleotide synthesis market. A thorough analysis of the key industry players has been conducted to provide insights into their business overview, solutions, and services; key strategies; new product & service launches, acquisitions, and recent developments associated with the oligonucleotide synthesis market. This report covers the competitive analysis of upcoming startups in the oligonucleotide synthesis market ecosystem.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing the closest approximations of the revenue numbers for the oligonucleotide synthesis market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide information on the key market drivers, restraints, challenges, trends, and opportunities.

The report provides insights on the following :

• Analysis of key drivers (Increasing use of synthesized oligos in therapeutic and diagnostic applications, technological advancements in oligonucleotide synthesis, growing government investments in life science research & synthetic biology, and growing focus on personalized medicine), restraints (Complexities associated with oligonucleotide-based drugs), opportunities (Increasing pharma R&D investments in emerging economies), and challenges (Lack of standard regulations, challenges in targeted delivery of oligonucleotides) are influencing the growth of the oligonucleotide synthesis market.
• Product Approvals: Detailed insights on newly approved products of the oligonucleotide synthesis market.
• Market Development: Comprehensive information about lucrative markets - the report analyses the oligonucleotide synthesis market across varied regions.
• Market Diversification: Exhaustive information about new products, recent developments, and investments in the oligonucleotide synthesis market.
• Pipeline Analysis: Comprehensive information about products under clinical trials.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players, including Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), and Merck KGaA (Germany), among others offering products for research & diagnostic applications. Other companies include Biogen (US), Alnylam Pharmaceuticals, Inc. (US), and Sarepta Therapeutics, Inc. (US), among others, for the therapeutic applications segment.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 INCLUSIONS & EXCLUSIONS
• 1.4 MARKET SCOPE
  • 1.4.1 YEARS CONSIDERED
  • 1.4.2 CURRENCY CONSIDERED
• 1.5 RESEARCH LIMITATIONS
• 1.6 STAKEHOLDERS
• 1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
  • 2.1.2 PRIMARY DATA
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 MARKET SIZE ASSESSMENT, SEGMENT LEVEL
• 2.3 MARKET GROWTH FORECAST
• 2.4 OLIGONUCLEOTIDE-BASED DRUGS MARKET VOLUME ESTIMATION
• 2.5 MARKET BREAKDOWN & DATA TRIANGULATION
• 2.6 STUDY ASSUMPTIONS
• 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 OLIGONUCLEOTIDE SYNTHESIS MARKET OVERVIEW
• 4.2 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION & COUNTRY (2024)
• 4.3 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2025 VS. 2030
• 4.4 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2024
• 4.5 OLIGONUCLEOTIDE SYNTHESIS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Increasing use of synthesized oligos in therapeutic & diagnostic applications
    • 5.2.1.2 Technological advancements
    • 5.2.1.3 Growing government investments in life science research & synthetic biology
    • 5.2.1.4 Growing focus on precision/personalized medicine
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Complexities associated with therapeutic oligonucleotides
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Increasing R&D investments by key players in emerging economies
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Lack of standard regulations
    • 5.2.4.2 Delivery of oligonucleotide drugs to specific targets
• 5.3 INDUSTRY TRENDS
  • 5.3.1 GROWING FOCUS ON DEVELOPMENT OF DRUG DELIVERY TECHNOLOGIES FOR OLIGONUCLEOTIDE-BASED DRUGS
  • 5.3.2 GROWING FOCUS ON TECHNOLOGY DEVELOPMENT FOR SUSTAINABLE & LARGE-SCALE SYNTHESIS OF OLIGONUCLEOTIDES
  • 5.3.3 FOCUS ON ACQUISITIONS TO ENHANCE MARKET POSITION
  • 5.3.4 GROWING USE OF ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS FOR TREATMENT OF NEUROLOGICAL & RARE DISEASES
• 5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.5 VALUE CHAIN ANALYSIS
• 5.6 ECOSYSTEM ANALYSIS
  • 5.6.1 ROLE IN ECOSYSTEM
• 5.7 TECHNOLOGY ANALYSIS
  • 5.7.1 KEY TECHNOLOGIES
    • 5.7.1.1 Solid-phase synthesis
    • 5.7.1.2 Liquid-phase synthesis
    • 5.7.1.3 Enzymatic oligo synthesis
  • 5.7.2 COMPLEMENTARY TECHNOLOGIES
    • 5.7.2.1 Polymerase chain reaction (PCR)
    • 5.7.2.2 Next-generation sequencing
    • 5.7.2.3 Microarray analysis
  • 5.7.3 ADJACENT TECHNOLOGIES
    • 5.7.3.1 CRISPR
    • 5.7.3.2 Lipid nanoparticles
• 5.8 PRICING ANALYSIS
  • 5.8.1 AVERAGE SELLING PRICE TREND OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS, BY KEY PLAYERS, 2022-2024
  • 5.8.2 AVERAGE SELLING PRICE TREND OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS, 2022-2024
  • 5.8.3 AVERAGE SELLING PRICE TREND OF OLIGONUCLEOTIDE-BASED DRUGS, BY KEY PLAYERS, 2022-2024
  • 5.8.4 AVERAGE SELLING PRICE OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS, BY REGION, 2024
  • 5.8.5 AVERAGE PRICING TREND OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS, BY KEY PLAYERS, 2024
  • 5.8.6 AVERAGE PRICING TREND OF OLIGONUCLEOTIDE-BASED DRUGS, BY REGION, 2024
• 5.9 PATENT ANALYSIS
  • 5.9.1 PATENTS FILED, BY DOCUMENT TYPE, 2014-2024
• 5.10 PIPELINE ANALYSIS
• 5.11 TRADE ANALYSIS
  • 5.11.1 IMPORT DATA (HS CODE 293499)
  • 5.11.2 EXPORT DATA (HS CODE 293499)
• 5.12 KEY CONFERENCES & EVENTS, 2025-2026
• 5.13 TARIFF & REGULATORY LANDSCAPE
  • 5.13.1 TARIFF DATA (HS CODE 2934.99, 3822.00)
    • 5.13.1.1 Trade policy updates affecting oligonucleotide synthesis market, 2022-2025
    • 5.13.1.2 Impact of Tariffs on pricing & supply chain
  • 5.13.2 REGULATORY BODIES, GOVERNMENT AGENCIES AND OTHER ORGANIZATIONS
  • 5.13.3 REGULATORY FRAMEWORK
• 5.14 PORTER'S FIVE FORCES ANALYSIS
  • 5.14.1 DEGREE OF COMPETITION
  • 5.14.2 BARGAINING POWER OF SUPPLIERS
  • 5.14.3 BARGAINING POWER OF BUYERS
  • 5.14.4 THREAT OF SUBSTITUTES
  • 5.14.5 THREAT OF NEW ENTRANTS
• 5.15 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.15.2 BUYING CRITERIA FOR END USERS
• 5.16 CASE STUDY ANALYSIS
  • 5.16.1 CASE STUDY 1: THERMO FISHER SCIENTIFIC LEVERAGED ITS OLIGONUCLEOTIDE SYNTHESIS EXPERTISE TO DELIVER LARGE-SCALE DYE-LABELED OLIGONUCLEOTIDES TO ITS CLIENT
  • 5.16.2 CASE STUDY 2: BAKER LAB UTILIZING TWIST BIOSCIENCES OLIGO POOLS FOR EVALUATING PROTEIN FOLDING
  • 5.16.3 CASE STUDY 3: ENHANCED MOTOR FUNCTION WITH SPINRAZA TREATMENT IN ADOLESCENTS WITH LATE-ONSET SMA
• 5.17 INVESTMENT/FUNDING SCENARIO
• 5.18 IMPACT OF GENERATIVE AI ON OLIGONUCLEOTIDE SYNTHESIS MARKET
• 5.19 TRUMP TARIFF IMPACT OVERVIEW: OLIGONUCLEOTIDE SYNTHESIS MARKET
  • 5.19.1 KEY TARIFF RATES
  • 5.19.2 PRICE IMPACT ANALYSIS
  • 5.19.3 KEY IMPACT ON VARIOUS REGIONS
    • 5.19.3.1 US
    • 5.19.3.2 Europe
    • 5.19.3.3 APAC
    • 5.19.3.4 Rest of the World
  • 5.19.4 END-USE INDUSTRY IMPACT
    • 5.19.4.1 Hospitals
    • 5.19.4.2 Pharmaceutical & biotechnology companies
    • 5.19.4.3 Diagnostic laboratories
    • 5.19.4.4 CROs & CDMOs
    • 5.19.4.5 Academic & research institutes

6 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT

• 6.1 INTRODUCTION
• 6.2 OLIGONUCLEOTIDE-BASED DRUGS
  • 6.2.1 OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE
    • 6.2.1.1 Antisense oligonucleotide-based drugs
      • 6.2.1.1.1 Growing use of antisense oligos in oligonucleotide-based drugs to boost growth
    • 6.2.1.2 siRNA oligonucleotide-based drugs
      • 6.2.1.2.1 Large pipeline of products to favor market growth
    • 6.2.1.3 Other oligonucleotide-based drugs
• 6.3 SYNTHESIZED OLIGONUCLEOTIDES
  • 6.3.1 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT
    • 6.3.1.1 Primers
      • 6.3.1.1.1 Increasing applications of oligo primers in DNA sequencing and molecular diagnostics to drive growth
    • 6.3.1.2 Probes
      • 6.3.1.2.1 Advancements in molecular diagnostic technologies such as FISH and qPCR to support market growth
    • 6.3.1.3 DNA oligonucleotides
      • 6.3.1.3.1 Diverse usage of DNA oligos to support market growth
    • 6.3.1.4 RNA oligonucleotides
      • 6.3.1.4.1 Growing diagnostic and therapeutic applications of RNA oligos to propel growth
    • 6.3.1.5 Other synthesized oligonucleotides
  • 6.3.2 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE
    • 6.3.2.1 Custom oligonucleotides
      • 6.3.2.1.1 Increasing demand for custom oligonucleotides for therapeutic research studies to drive growth
    • 6.3.2.2 Predesigned oligonucleotides
      • 6.3.2.2.1 Ability of predesigned oligos to save time required in design and optimization to boost adoption
• 6.4 REAGENTS & CONSUMABLES
  • 6.4.1 GROWING DEMAND FOR OLIGOS IN SEQUENCING, DRUG DESIGN, AND GENE SYNTHESIS TO DRIVE MARKET GROWTH FOR REAGENTS
• 6.5 EQUIPMENT
  • 6.5.1 TECHNOLOGICAL INNOVATIONS IN OLIGONUCLEOTIDE SYNTHESIZERS TO DRIVE GROWTH IN EQUIPMENT MARKET

7 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION

• 7.1 INTRODUCTION
• 7.2 THERAPEUTIC APPLICATIONS
  • 7.2.1 THERAPEUTIC APPLICATIONS MARKET, BY DISEASE TYPE
    • 7.2.1.1 Neurological disorders
      • 7.2.1.1.1 Growing research on oligonucleotide-based drugs for treatment of DMD and SMA to drive market
    • 7.2.1.2 Rare diseases
      • 7.2.1.2.1 High specificity & efficacy of oligo-based drugs against rare diseases to support growth
    • 7.2.1.3 Other diseases
• 7.3 RESEARCH APPLICATIONS
  • 7.3.1 PCR
    • 7.3.1.1 Increasing use of PCR in molecular biology research to drive market
  • 7.3.2 SEQUENCING
    • 7.3.2.1 Advancements in sequencing technologies & low cost of DNA sequencing to boost market
  • 7.3.3 OTHER RESEARCH APPLICATIONS
• 7.4 DIAGNOSTIC APPLICATIONS
  • 7.4.1 INCREASING DEMAND FOR RAPID & SPECIFIC METHODS FOR DISEASE DETECTION SUPPORT MARKET GROWTH

8 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER

• 8.1 INTRODUCTION
• 8.2 HOSPITALS
  • 8.2.1 INCREASING FDA APPROVALS FOR OLIGONUCLEOTIDE-BASED DRUGS FOR RARE DISEASES TO DRIVE MARKET
• 8.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 8.3.1 GROWING APPLICATIONS OF OLIGOS IN DRUG DISCOVERY & THERAPEUTICS TO PROPEL MARKET
• 8.4 DIAGNOSTIC LABORATORIES
  • 8.4.1 RISING SIGNIFICANCE OF OLIGOS IN MOLECULAR DIAGNOSTICS TO FUEL MARKET
• 8.5 CONTRACT RESEARCH ORGANIZATIONS (CROS) & CONTRACT MANUFACTURING ORGANIZATIONS (CMOS)
  • 8.5.1 WIDE RANGE OF CUSTOMIZED OLIGO SERVICES TO SUPPORT MARKET GROWTH
• 8.6 ACADEMIC RESEARCH INSTITUTES
  • 8.6.1 GROWING USE OF OLIGOS FOR GENOMIC RESEARCH APPLICATIONS TO PROPEL MARKET

9 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY REGION

• 9.1 INTRODUCTION
• 9.2 NORTH AMERICA
  • 9.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK
  • 9.2.2 US
    • 9.2.2.1 Government initiatives and strategic developments by leading players to drive market
  • 9.2.3 CANADA
    • 9.2.3.1 Strong research infrastructure and availability of funding to support market growth
• 9.3 EUROPE
  • 9.3.1 EUROPE: MACROECONOMIC OUTLOOK
  • 9.3.2 GERMANY
    • 9.3.2.1 Government & private funding investments towards health research to drive market
  • 9.3.3 UK
    • 9.3.3.1 Strategic collaborations & partnerships between key market players to fuel market
  • 9.3.4 FRANCE
    • 9.3.4.1 Favorable government initiatives for genomics research to boost demand
  • 9.3.5 ITALY
    • 9.3.5.1 Increasing R&D expenditure for pharma & biotech companies to support market growth
  • 9.3.6 SPAIN
    • 9.3.6.1 Favorable funding investments for biomedical research to drive market
  • 9.3.7 REST OF EUROPE
• 9.4 ASIA PACIFIC
  • 9.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK
  • 9.4.2 CHINA
    • 9.4.2.1 Expansion of leading pharmaceutical & biotechnology companies to drive market
  • 9.4.3 JAPAN
    • 9.4.3.1 Growing research initiatives & strategic developments to boost demand
  • 9.4.4 INDIA
    • 9.4.4.1 Development of bioclusters and improvements in healthcare infrastructure to propel market
  • 9.4.5 AUSTRALIA
    • 9.4.5.1 Increasing government initiatives and research funding to support market growth
  • 9.4.6 SOUTH KOREA
    • 9.4.6.1 Growing research activities and strategic expansions in oligonucleotide synthesis to aid market
  • 9.4.7 REST OF ASIA PACIFIC
• 9.5 LATIN AMERICA
  • 9.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK
  • 9.5.2 BRAZIL
    • 9.5.2.1 Availability of leading oligo-based therapies to support market growth
  • 9.5.3 MEXICO
    • 9.5.3.1 Growing adoption of NGS technology to drive market
  • 9.5.4 ARGENTINA
    • 9.5.4.1 Increasing research collaborations and government support to boost market
  • 9.5.5 REST OF LATIN AMERICA
• 9.6 MIDDLE EAST
  • 9.6.1 MIDDLE EAST: MACROECONOMIC OUTLOOK
  • 9.6.2 GCC COUNTRIES
    • 9.6.2.1 Saudi Arabia (KSA)
      • 9.6.2.1.1 Increasing focus on research & government support to propel market
    • 9.6.2.2 United Arab Emirates (UAE)
      • 9.6.2.2.1 Growing focus on life sciences research to fuel market
    • 9.6.2.3 Other GCC countries
  • 9.6.3 REST OF MIDDLE EAST
• 9.7 AFRICA
  • 9.7.1 IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH
  • 9.7.2 AFRICA: MACROECONOMIC OUTLOOK

10 COMPETITIVE LANDSCAPE

• 10.1 INTRODUCTION
• 10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
• 10.3 REVENUE ANALYSIS (RESEARCH & DIAGNOSTIC APPLICATIONS)
  • 10.3.1 REVENUE ANALYSIS (RESEARCH & DIAGNOSTIC APPLICATIONS), 2022-2024
  • 10.3.2 REVENUE ANALYSIS (THERAPEUTIC APPLICATIONS), 2022-2024
• 10.4 MARKET SHARE ANALYSIS
  • 10.4.1 MARKET SHARE ANALYSIS (RESEARCH & DIAGNOSTIC APPLICATIONS), 2024
  • 10.4.2 MARKET SHARE ANALYSIS (THERAPEUTIC APPLICATIONS),2024
• 10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS (RESEARCH & DIAGNOSTIC APPLICATIONS), 2024
  • 10.5.1 STARS
  • 10.5.2 EMERGING LEADERS
  • 10.5.3 PERVASIVE PLAYERS
  • 10.5.4 PARTICIPANTS
• 10.6 COMPANY EVALUATION MATRIX: KEY PLAYERS (THERAPEUTIC APPLICATIONS), 2024
  • 10.6.1 STARS
  • 10.6.2 EMERGING LEADERS
  • 10.6.3 PERVASIVE PLAYERS
  • 10.6.4 PARTICIPANTS
  • 10.6.5 COMPANY FOOTPRINT:
    • 10.6.5.1 Company footprint (Research & diagnostic applications)
    • 10.6.5.2 Region footprint (Research & diagnostic applications)
    • 10.6.5.3 Product footprint (Research & diagnostic applications)
    • 10.6.5.4 Application footprint (Research & diagnostic applications)
    • 10.6.5.5 Company footprint (Therapeutic applications)
    • 10.6.5.6 Region footprint (Therapeutic applications)
    • 10.6.5.7 Product footprint (Therapeutic applications)
    • 10.6.5.8 Application footprint (Therapeutic applications)
• 10.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 10.7.1 PROGRESSIVE COMPANIES
  • 10.7.2 RESPONSIVE COMPANIES
  • 10.7.3 DYNAMIC COMPANIES
  • 10.7.4 STARTING BLOCKS
  • 10.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
    • 10.7.5.1 Detailed list of key startups/SMEs
    • 10.7.5.2 Competitive benchmarking of startups/SMEs
• 10.8 COMPANY VALUATION & FINANCIAL METRICS
  • 10.8.1 FINANCIAL METRICS (RESEARCH & DIAGNOSTIC APPLICATIONS)
  • 10.8.2 COMPANY VALUATION (RESEARCH & DIAGNOSTIC APPLICATIONS)
  • 10.8.3 FINANCIAL METRICS (THERAPEUTIC APPLICATIONS)
  • 10.8.4 COMPANY VALUATION (THERAPEUTIC APPLICATIONS)
• 10.9 BRAND/PRODUCT COMPARATIVE ANALYSIS
  • 10.9.1 BRAND/PRODUCT COMPARATIVE ANALYSIS, BY PRODUCT (RESEARCH & DIAGNOSTIC APPLICATIONS)
  • 10.9.2 BRAND/PRODUCT COMPARATIVE ANALYSIS, BY PRODUCT (THERAPEUTIC APPLICATIONS)
• 10.10 COMPETITIVE SCENARIO
  • 10.10.1 PRODUCT APPROVALS

11 COMPANY PROFILES

• 11.1 KEY PLAYERS (RESEARCH & DIAGNOSTIC APPLICATIONS)
  • 11.1.1 DANAHER CORPORATION
    • 11.1.1.1 Business overview
    • 11.1.1.2 Products offered
    • 11.1.1.3 Recent developments
      • 11.1.1.3.1 Deals
      • 11.1.1.3.2 Expansions
      • 11.1.1.3.3 Other developments
    • 11.1.1.4 MnM view
      • 11.1.1.4.1 Key strengths
      • 11.1.1.4.2 Strategic choices
      • 11.1.1.4.3 Weaknesses & competitive threats
  • 11.1.2 THERMO FISHER SCIENTIFIC INC.
    • 11.1.2.1 Business overview
    • 11.1.2.2 Products offered
    • 11.1.2.3 Recent developments
      • 11.1.2.3.1 Deals
    • 11.1.2.4 MnM view
      • 11.1.2.4.1 Key strengths
      • 11.1.2.4.2 Strategic choices
      • 11.1.2.4.3 Weaknesses & competitive threats
  • 11.1.3 MERCK KGAA
    • 11.1.3.1 Business overview
    • 11.1.3.2 Products offered
    • 11.1.3.3 Recent developments
      • 11.1.3.3.1 Deals
      • 11.1.3.3.2 Expansions
    • 11.1.3.4 MnM view
      • 11.1.3.4.1 Key strengths
      • 11.1.3.4.2 Strategic choices
      • 11.1.3.4.3 Weaknesses & competitive threats
  • 11.1.4 LGC LIMITED
    • 11.1.4.1 Business overview
    • 11.1.4.2 Products offered
    • 11.1.4.3 Recent developments
      • 11.1.4.3.1 Deals
      • 11.1.4.3.2 Expansions
    • 11.1.4.4 MnM view
      • 11.1.4.4.1 Key strengths
      • 11.1.4.4.2 Strategic choices
      • 11.1.4.4.3 Weaknesses & competitive threats
  • 11.1.5 EUROFINS SCIENTIFIC
    • 11.1.5.1 Business overview
    • 11.1.5.2 Products offered
    • 11.1.5.3 Recent developments
      • 11.1.5.3.1 Deals
      • 11.1.5.3.2 Expansions
    • 11.1.5.4 MnM view
      • 11.1.5.4.1 Key strengths
      • 11.1.5.4.2 Strategic choices
      • 11.1.5.4.3 Weaknesses & competitive threats
  • 11.1.6 AGILENT TECHNOLOGIES, INC.
    • 11.1.6.1 Business overview
    • 11.1.6.2 Products offered
    • 11.1.6.3 Recent developments
      • 11.1.6.3.1 Deals
      • 11.1.6.3.2 Expansions
  • 11.1.7 KANEKA CORPORATION
    • 11.1.7.1 Business overview
    • 11.1.7.2 Products offered
    • 11.1.7.3 Recent developments
      • 11.1.7.3.1 Expansions
  • 11.1.8 MARAVAI LIFESCIENCES
    • 11.1.8.1 Business overview
    • 11.1.8.2 Products offered
    • 11.1.8.3 Recent developments
      • 11.1.8.3.1 Deals
      • 11.1.8.3.2 Expansions
  • 11.1.9 AZENTA US INC.
    • 11.1.9.1 Business overview
    • 11.1.9.2 Products offered
  • 11.1.10 TWIST BIOSCIENCE
    • 11.1.10.1 Business overview
    • 11.1.10.2 Products offered
    • 11.1.10.3 Recent developments
      • 11.1.10.3.1 Deals
  • 11.1.11 GENSCRIPT
    • 11.1.11.1 Business overview
    • 11.1.11.2 Products offered
    • 11.1.11.3 Recent developments
      • 11.1.11.3.1 Deals
      • 11.1.11.3.2 Expansions
• 11.2 KEY PLAYERS (THERAPEUTIC APPLICATIONS)
  • 11.2.1 BIOGEN
    • 11.2.1.1 Business overview
    • 11.2.1.2 Products offered
    • 11.2.1.3 Recent developments
      • 11.2.1.3.1 Product approvals
      • 11.2.1.3.2 Deals
      • 11.2.1.3.3 Expansions
    • 11.2.1.4 MnM view
      • 11.2.1.4.1 Key strengths
      • 11.2.1.4.2 Strategic choices
      • 11.2.1.4.3 Weaknesses & competitive threats
  • 11.2.2 ALNYLAM PHARMACEUTICALS, INC.
    • 11.2.2.1 Business overview
    • 11.2.2.2 Products offered
    • 11.2.2.3 Recent developments
      • 11.2.2.3.1 Product approvals
      • 11.2.2.3.2 Deals
    • 11.2.2.4 MnM view
      • 11.2.2.4.1 Key strengths
      • 11.2.2.4.2 Strategic choices
      • 11.2.2.4.3 Weaknesses & competitive threats
  • 11.2.3 SAREPTA THERAPEUTICS, INC.
    • 11.2.3.1 Business overview
    • 11.2.3.2 Products offered
    • 11.2.3.3 Recent developments
      • 11.2.3.3.1 Product approvals
      • 11.2.3.3.2 Expansions
    • 11.2.3.4 MnM view
      • 11.2.3.4.1 Key strengths
      • 11.2.3.4.2 Strategic choices
      • 11.2.3.4.3 Weaknesses & competitive threats
  • 11.2.4 ASTRAZENECA
    • 11.2.4.1 Business overview
    • 11.2.4.2 Products offered
    • 11.2.4.3 Recent developments
      • 11.2.4.3.1 Deals
      • 11.2.4.3.2 Product Approvals
    • 11.2.4.4 MnM view
      • 11.2.4.4.1 Key strengths
      • 11.2.4.4.2 Strategic choices
      • 11.2.4.4.3 Weaknesses & competitive threats
  • 11.2.5 ASTELLAS PHARMA INC.
    • 11.2.5.1 Business overview
    • 11.2.5.2 Products offered
    • 11.2.5.3 Recent developments
      • 11.2.5.3.1 Deals
      • 11.2.5.3.2 Product approvals
    • 11.2.5.4 MnM view
      • 11.2.5.4.1 Key strengths
      • 11.2.5.4.2 Strategic choices
      • 11.2.5.4.3 Weaknesses & competitive threats
  • 11.2.6 JAZZ PHARMACEUTICALS PLC
    • 11.2.6.1 Business overview
    • 11.2.6.2 Products offered
  • 11.2.7 NIPPON SHINYAKU, CO. LTD.
    • 11.2.7.1 Business overview
    • 11.2.7.2 Products offered
    • 11.2.7.3 Recent developments
      • 11.2.7.3.1 Deals
  • 11.2.8 IONIS PHARMACEUTICALS, INC.
    • 11.2.8.1 Business overview
    • 11.2.8.2 Products offered
    • 11.2.8.3 Recent developments
      • 11.2.8.3.1 Product Approvals
      • 11.2.8.3.2 Deals
  • 11.2.9 NOVARTIS AG
    • 11.2.9.1 Business overview
    • 11.2.9.2 Products offered
    • 11.2.9.3 Recent developments
      • 11.2.9.3.1 Product Approvals
      • 11.2.9.3.2 Deals
• 11.3 OTHER PLAYERS
  • 11.3.1 OLIGOMAKER APS (PART OF TAG COPENHAGEN A/S)
  • 11.3.2 BIOLEGIO B.V.
  • 11.3.3 BIOLYTIC LAB PERFORMANCE, INC.
  • 11.3.4 BIOCOMMA LIMITED
  • 11.3.5 REVVITY (SUBSIDIARY OF HORIZON DISCOVERY LTD.)
  • 11.3.6 BIO-SYNTHESIS, INC.
  • 11.3.7 CREATIVE BIOGENE
  • 11.3.8 REPROCELL INC. (THROUGH SUBSIDIARY BIOSERVE)

12 APPENDIX

• 12.1 DISCUSSION GUIDE
• 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 12.3 CUSTOMIZATION OPTIONS
• 12.4 RELATED REPORTS
• 12.5 AUTHOR DETAILS

관련자료